- Home
- JAZZ
as of 12-05-2025 3:58pm EST
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
| Founded: | 2003 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 10.8B | IPO Year: | 2007 |
| Target Price: | $194.40 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $95.49 - $182.99 | Next Earning Date: | 11-05-2025 |
| Revenue: | $4,157,832,999 | Revenue Growth: | 4.14% |
| Revenue Growth (this year): | 6% | Revenue Growth (next year): | 6.84% |
AI-Powered JAZZ Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Jazz Pharmaceuticals plc (Ireland) (JAZZ)
Director
Avg Cost/Share
$178.59
Shares
77,500
Total Value
$13,780,337.23
Owned After
393,332
Director
Avg Cost/Share
$177.78
Shares
3,415
Total Value
$607,126.55
Owned After
20,449
SEC Form 4
Director
Avg Cost/Share
$180.86
Shares
5,500
Total Value
$994,728.35
Owned After
8,893
SEC Form 4
Director
Avg Cost/Share
$181.35
Shares
18,000
Total Value
$3,259,537.81
Owned After
393,332
SVP, Chief Accounting Officer
Avg Cost/Share
$181.87
Shares
5,319
Total Value
$968,402.04
Owned After
7,012
EVP, Global Head of R&D & CMO
Avg Cost/Share
$168.26
Shares
7,159
Total Value
$1,204,573.34
Owned After
72,628
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| COZADD BRUCE C | JAZZ | Director | Nov 26, 2025 | Sell | $178.59 | 77,500 | $13,780,337.23 | 393,332 | |
| McSharry Heather Ann | JAZZ | Director | Nov 20, 2025 | Sell | $177.78 | 3,415 | $607,126.55 | 20,449 | |
| Winningham Rick E | JAZZ | Director | Nov 18, 2025 | Sell | $180.86 | 5,500 | $994,728.35 | 8,893 | |
| COZADD BRUCE C | JAZZ | Director | Nov 18, 2025 | Sell | $181.35 | 18,000 | $3,259,537.81 | 393,332 | |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Nov 18, 2025 | Sell | $181.87 | 5,319 | $968,402.04 | 7,012 | |
| Iannone Robert | JAZZ | EVP, Global Head of R&D & CMO | Nov 17, 2025 | Sell | $168.26 | 7,159 | $1,204,573.34 | 72,628 |
Compare JAZZ vs Leading Stocks
See how JAZZ stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "JAZZ Jazz Pharmaceuticals plc (Ireland) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.